Beta Bionics, Inc. (BBNX)

Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $981.12 million. The enterprise value is $719.83 million.

Market Cap	981.12M
Enterprise Value	719.83M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Bionics has 43.47 million shares outstanding. The number of shares has increased by 312.49% in one year.

Current Share Class	43.47M
Shares Outstanding	43.47M
Shares Change (YoY)	+312.49%
Shares Change (QoQ)	+41.27%
Owned by Insiders (%)	3.67%
Owned by Institutions (%)	69.47%
Float	21.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.21
Forward PS	8.88
PB Ratio	3.19
P/TBV Ratio	3.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	9.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.68, with a Debt / Equity ratio of 0.02.

Current Ratio	14.68
Quick Ratio	13.40
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-20.14%
Revenue Per Employee	$265,381
Profits Per Employee	-$249,554
Employee Count	294
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	19.44
200-Day Moving Average	n/a
Relative Strength Index (RSI)	55.90
Average Volume (20 Days)	1,067,208

Short Selling Information

The latest short interest is 3.88 million, so 8.93% of the outstanding shares have been sold short.

Short Interest	3.88M
Short Previous Month	3.11M
Short % of Shares Out	8.93%
Short % of Float	18.13%
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $78.02 million and -$73.37 million in losses. Loss per share was -$3.35.

Revenue	78.02M
Gross Profit	42.08M
Operating Income	-62.53M
Pretax Income	-73.37M
Net Income	-73.37M
EBITDA	-61.31M
EBIT	-62.53M
Loss Per Share	-$3.35

Balance Sheet

The company has $249.72 million in cash and $6.69 million in debt, giving a net cash position of $243.03 million or $5.59 per share.

Cash & Cash Equivalents	249.72M
Total Debt	6.69M
Net Cash	243.03M
Net Cash Per Share	$5.59
Equity (Book Value)	301.63M
Book Value Per Share	6.94
Working Capital	266.59M

Cash Flow

In the last 12 months, operating cash flow was -$57.46 million and capital expenditures -$4.59 million, giving a free cash flow of -$62.06 million.

Operating Cash Flow	-57.46M
Capital Expenditures	-4.59M
Free Cash Flow	-62.06M
FCF Per Share	-$1.43

Margins

Gross margin is 53.93%, with operating and profit margins of -80.14% and -94.04%.

Gross Margin	53.93%
Operating Margin	-80.14%
Pretax Margin	-94.04%
Profit Margin	-94.04%
EBITDA Margin	-78.58%
EBIT Margin	-80.14%
FCF Margin	n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-312.49%
Shareholder Yield	-312.49%
Earnings Yield	-7.62%
FCF Yield	-6.44%

Analyst Forecast

The average price target for Beta Bionics is $26.10, which is 15.64% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26.10
Price Target Difference	15.64%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Beta Bionics has an Altman Z-Score of 13.78 and a Piotroski F-Score of 3.

Altman Z-Score	13.78
Piotroski F-Score	3